Drug Farm

Executive Summary

Drug Farm is a Shanghai-based biotechnology company applying artificial intelligence and genetics to discover first-in-class therapies for infectious diseases and cancer. Its proprietary IDInVivo+ platform integrates in vivo validation with AI-driven target identification to accelerate drug development. The company's pipeline focuses on challenging conditions such as hepatitis B and solid tumors, where current treatments are limited. Founded in 2018, Drug Farm operates at the preclinical stage and has assembled a team of 50–200 employees. Despite being private and early-stage, its innovative platform positions it as a potential player in the AI-driven drug discovery space. The company has not disclosed total funding or valuation, but its approach aligns with industry trends toward precision medicine and computational biology. Drug Farm's success hinges on advancing its lead candidates through preclinical studies and securing partnerships for clinical development.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Hepatitis B Candidate40% success
• Q3 2026Preclinical Data Readout for Lead Solid Tumor Program50% success
• TBDStrategic Partnership or Collaboration Announcement30% success